Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.
Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM. Jiang Y, et al. Among authors: parsa s. Cancer Discov. 2017 Jan;7(1):38-53. doi: 10.1158/2159-8290.CD-16-0975. Epub 2016 Oct 12. Cancer Discov. 2017. PMID: 27733359 Free PMC article.
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing.
Parsa S, Ortega-Molina A, Ying HY, Jiang M, Teater M, Wang J, Zhao C, Reznik E, Pasion JP, Kuo D, Mohan P, Wang S, Camarillo JM, Thomas PM, Jain N, Garcia-Bermudez J, Cho BK, Tam W, Kelleher NL, Socci N, Dogan A, De Stanchina E, Ciriello G, Green MR, Li S, Birsoy K, Melnick AM, Wendel HG. Parsa S, et al. Nat Cancer. 2020;1:653-664. doi: 10.1038/s43018-020-0080-0. Epub 2020 Jun 22. Nat Cancer. 2020. PMID: 33569544 Free PMC article.
SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma.
Portelinha A, Wang S, Parsa S, Jiang M, Gorelick AN, Mohanty S, Sharma S, de Stanchina E, Berishaj M, Zhao C, Heward J, Aryal NK, Tavana O, Wen J, Fitzgibbon J, Dogan A, Younes A, Melnick AM, Wendel HG. Portelinha A, et al. Among authors: parsa s. J Exp Med. 2024 Oct 7;221(10):e20231143. doi: 10.1084/jem.20231143. Epub 2024 Sep 5. J Exp Med. 2024. PMID: 39235528
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Bibikova E, Parsa S, Floren M, Law B, Clevenger T, Cheung J, De Jesus G, Burke K, Gulrajani M, Yamaguchi K, Do P, Dougherty B, Whitston D, Brock G, Munugalavadla V, Frigault MM, Hartmann TN, Byrd JC, Furman RR, Brown JR, Covey T, Mortlock A. Bibikova E, et al. Among authors: parsa s. Hematol Oncol. 2025 Jan;43(1):e70008. doi: 10.1002/hon.70008. Hematol Oncol. 2025. PMID: 39716442 Clinical Trial.
A blended genome and exome sequencing method captures genetic variation in an unbiased, high-quality, and cost-effective manner.
Boltz TA, Chu BB, Liao C, Sealock JM, Ye R, Majara L, Fu JM, Service S, Zhan L, Medland SE, Chapman SB, Rubinacci S, DeFelice M, Grimsby JL, Abebe T, Alemayehu M, Ashaba FK, Atkinson EG, Bigdeli T, Bradway AB, Brand H, Chibnik LB, Fekadu A, Gatzen M, Gelaye B, Gichuru S, Gildea ML, Hill TC, Huang H, Hubbard KM, Injera WE, James R, Joloba M, Kachulis C, Kalmbach PR, Kamulegeya R, Kigen G, Kim S, Koen N, Kwobah EK, Kyebuzibwa J, Lee S, Lennon NJ, Lind PA, Lopera-Maya EA, Makale J, Mangul S, McMahon J, Mowlem P, Musinguzi H, Mwema RM, Nakasujja N, Newman CP, Nkambule LL, O'Neil CR, Olivares AM, Olsen CM, Ongeri L, Parsa SJ, Pretorius A, Ramesar R, Reagan FL, Sabatti C, Schneider JA, Shiferaw W, Stevenson A, Stricker E, Stroud RE 2nd, Tang J, Whiteman D, Yohannes MT, Yu M, Yuan K; NeuroGAP-Psychosis; Akena D, Atwoli L, Kariuki SM, Koenen KC, Newton CRJC, Stein DJ, Teferra S, Zingela Z, Pato CN, Pato MT, Lopez-Jaramillo C, Freimer N, Ophoff RA, Olde Loohuis LM, Talkowski ME, Neale BM, Howrigan DP, Martin AR. Boltz TA, et al. Among authors: parsa sj. bioRxiv [Preprint]. 2024 Sep 8:2024.09.06.611689. doi: 10.1101/2024.09.06.611689. bioRxiv. 2024. PMID: 39282356 Free PMC article. Preprint.
Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.
Parsa S, Jain SS, Akinrimisi O, Lam CSP, Mahaffey KW. Parsa S, et al. Cardiol Ther. 2024 Dec;13(4):645-661. doi: 10.1007/s40119-024-00379-0. Epub 2024 Aug 17. Cardiol Ther. 2024. PMID: 39152241 Free PMC article. Review.
150 results